PROGRAMMA FINALE - ABSTRACTS ONLINE

SYMPOSIA ABSTRACTS

S-1 THE BIOBANK: USEFUL INSTRUMENT FOR ETHIC COMMITTEE
S-2 THE NEW ERA OF SIGNAL DETECTION AND VALIDATION IN PHARMACOVIGILANCE
S-3 DRUG INFORMATION
S-4 NEW FRONTIERS IN INFLAMMATION: THE GASOTRANSMITTERS AS NEW THERAPEUTIC TARGET
S-5 PERSONALIZED MEDICAL THERAPY: CURRENT STATUS AND PERSPECTIVES
S-6 A NEW ALLIANCE FOR THE RESEARCH: BOEHRINGER INGELHEIM & ELI LILLY, 20 YEARS TOGETHER TO FIND NEW SOLUTIONS IN DIABETES
S-7 YOUNG ITALIAN PHARMACOLOGISTS FACE THE FUTURE OF ALZHEIMER’S DISEASE TREATMENT
S-8 TOWARDS A SAFER ANTI-INFLAMMATORY THERAPY: WHERE DO WE STAND AT THE BEGINNING OF THE THIRD MILLENNIUM?
S-9 THE FUTURE OF CLINICAL RESERCH: REFLECTIONS AND PROPOSALS UPON POSSIBLE PERSPECTIVES
S-10 DABIGATRAN ETEXILATE, A NOVEL, REVERSIBLE, ORAL DIRECT THROMBIN INHIBITOR: PRECLINICAL PROFILE AND CLINICAL EVIDENCE
S-11 GLAUCOMA: PRESSURE OR PROTECTION
S-12 BASIC RESEARCH FOR DRUGABLE TARGETS DISCOVERY AND CELL THERAPY OF PAIN
S-13 EVOLUTION OF TREATMENT OF HORMONE-REFRACTORY PROSTATE CANCER
S-14 DOCTOR'S AND PATIENT'S APPRAISAL OF ADVERSE DRUG REACTIONS: COMPARING DIFFERENT VIEWS
S-15 NEW OPPORTUNITIES IN THE PHARMACOLOGY OF CORONARY THROMBOSIS
S-16 ITALIAN PHARMACOLOGISTS AND THE LAW N. 38: THE IMPACT PROJECT
S-17 PHARMACOGENETICS: RESEARCH EXPERIENCE OF CLINICAL REALITY? THE VIEWPOINT OF THE YOUNG INVESTIGATORS OF THE ITALIAN SOCIETY OF PHARMACOLOGY
S-18 NEW PERSPECTIVES IN THE RECEPTOR FUNCTION
S-19 SEROTONIN 5-HT2C RECEPTORS AS A TARGET FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS
S-20 FUNCTIONAL INTERACTIONS BETWEEN DOPAMINE AND OTHER NEUROTRANSMITTER SYSTEMS IN PARKINSON’S DISEASE AND DYSKINESIA: NEW POSSIBLE PHARMACOLOGICAL APPROACHE
S-21 MOR-NRI: A NEW CLASS OF ANALGESICS
S-22 ANTIMICROBIALS FOR GI INFECTIONS: CURRENT AND FUTURE DEVELOPMENTS
S-23 NUTRACEUTICALS, FOOD SUPPLEMENTATION AND BOTANICAL DRUGS: WHERE ARE WE?
S-24 PHARMACOVIGILANCE IN PEDIATRY
S-25 MECHANISMS AND TARGETS IN NEUROPHARMACOLOGY
S-26 MEDICINES AND INNOVATION: THERAPEUTIC NEEDS, SCIENTIFIC EVIDENCE, EUROPEAN SCENARIO
S-27 DIET AND CARDIOVASCULAR PREVENTION
S-28 PATENT EXPIRED DRUGS: BETWEEN EVIDENCE AND BIAS
S-29 DIRECTIVE 2010/63/EU ON THE PROTECTION OF ANIMALS USED FOR SCIENTIFIC PURPOSES: WHICH IMPLICATIONS FOR THE ITALIAN RESEARCH?
S-30 HERBAL MEDICINES IN EXPERIMENTAL ONCOLOGY
S-31 NEUROPROTECTION AND NEUROREGENERATION IN BRAIN ISCHEMIA
S-32 RECENT DEVELOPMENT IN THE PHARMACOLOGY OF GLUTAMATE
S-33 ROLE OF PURINERGIC SIGNALLING IN THE FUNCTION OF NEURAL AND PERIPHERAL CELLS
S-34 PHARMACOLOGICAL ACTIVATION OF THE CHOLINERGIC ANTI-INFLAMMATORY PATHWAY AS AN INNOVATIVE THERAPEUTIC STRATEGY AGAINST ORGAN DAMAGE
S-35 PREVENTION AND TREATMENT OF NSAID-GASTROPATHY: RECENT ADVANCES
S-36 NEW HORIZON IN IN THE MULTIPLE SCLEROSIS TREATMENT